Savara Inc (SVRA)

$5.12 -0.12 (-2.29%)
Market Cap 1.05B
Revenue (ttm) 0.00
Net Income (ttm) -118.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 1,132,100
Avg Vol 1,618,510
Day's Range N/A - N/A
Shares Out 204.92M
Stochastic %K 36%
Beta 0.28
Analysts Strong Sell
Price Target $10.81

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 512 614 1848
Address:
1717 Langhorne Newtown Road, Suite 300 One Summit Square, Langhorne, United States
Richterscale
Richterscale Apr. 30 at 7:28 PM
$SVRA news?
2 · Reply
PennOhio
PennOhio Apr. 29 at 3:29 PM
$SVRA I don’t take way that at all. The FDA asked for more data and that triggered further review per guidance/proceed.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 29 at 2:42 AM
$SVRA RSI: 31.30, MACD: -0.1010 Vol: 0.34, MA20: 5.55, MA50: 5.48 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Stormvyre
Stormvyre Apr. 25 at 6:26 AM
$SVRA 👀
0 · Reply
Danboo
Danboo Apr. 24 at 9:13 PM
$SVRA Surfactant dysfunction is a hallmark disease element of aPaP which the Savara investigational drug is designed to address. Similarly, surfactant dysfunction is a hallmark element of COPD. FDA approval of the Savara drug opens the door to investigational expansion or off-label therapeutic expansion into the COPD disease population. Medinfo
0 · Reply
Danboo
Danboo Apr. 24 at 8:47 PM
$SVRA When Savara first went public there was a massive dilution of then Savara stock into new shares. The current proxy statement now calls for approval of expanding share authorization from 300 M to 600M. This suggests that upon FDA approval Savara management may authorize a stock split to restore partially or entirely pre dilution shares to investors. Medinfo
2 · Reply
Richterscale
Richterscale Apr. 24 at 5:10 PM
$SVRA When s the buyout ?
0 · Reply
ckruel
ckruel Apr. 24 at 1:51 PM
$SVRA Oppenheimer analyst Mazahir Alimohamed assumed coverage of Savara (SVRA) with an Outperform rating with a price target of $11, up from $9. With Priority Review granted to the BLA for molgramostim, an inhaled GM-CSF therapy, Savara’s story has shifted toward regulatory execution and commercial positioning, the firm says. Robust data from Phase 3 IMPALA-2 in autoimmune PAP support the BLA package and the firm’s view of a high-probability approval story, also given that prior FDA feedback was only CMC-related.
0 · Reply
notreload_ai
notreload_ai Apr. 24 at 12:12 PM
Oppenheimer initiates coverage on $SVRA with an Outperform rating and a $11 price target, following the FDA Priority Review designation for molgramostim. https://notreload.xyz/xy/oppenheimer-turns-bullish-on-savara-as-molgramostim-moves-closer-to-approval/
0 · Reply
Richterscale
Richterscale Apr. 23 at 8:58 PM
$SVRA Re started position $4.94.
0 · Reply
Latest News on SVRA
Savara Announces New Employment Inducement Grant

Apr 17, 2026, 4:05 PM EDT - 15 days ago

Savara Announces New Employment Inducement Grant

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Apr 15, 2026, 4:05 PM EDT - 17 days ago

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Apr 14, 2026, 8:05 AM EDT - 19 days ago

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Apr 7, 2026, 8:05 AM EDT - 26 days ago

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 30, 2026, 8:05 AM EDT - 4 weeks ago

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 13, 2026, 8:05 AM EDT - 7 weeks ago

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Savara Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:10 AM EDT - 7 weeks ago

Savara Transcript: The Citizens Life Sciences Conference 2026

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Mar 6, 2026, 4:05 PM EST - 2 months ago

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Mar 4, 2026, 4:05 PM EST - 2 months ago

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 9:20 AM EST - 2 months ago

Savara Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Feb 20, 2026, 4:15 PM EST - 2 months ago

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 12:30 PM EST - 2 months ago

Savara Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Feb 4, 2026, 4:05 PM EST - 3 months ago

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

Jan 27, 2026, 8:05 AM EST - 3 months ago

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

HTGC

Savara Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 3 months ago

Savara Transcript: 44th Annual J.P. Morgan Healthcare Conference

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Jan 8, 2026, 4:05 PM EST - 4 months ago

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Dec 22, 2025, 8:30 AM EST - 4 months ago

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 8:05 AM EST - 4 months ago

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Dec 11, 2025, 8:05 AM EST - 5 months ago

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:00 AM EST - 5 months ago

Savara Transcript: Evercore ISI 8th Annual HealthCONx Conference

Savara Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 2:30 PM EST - 5 months ago

Savara Transcript: Piper Sandler 37th Annual Healthcare Conference

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Dec 2, 2025, 8:05 AM EST - 5 months ago

Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System

Savara Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 7:00 AM EST - 5 months ago

Savara Transcript: Jefferies London Healthcare Conference 2025

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 4:05 PM EST - 6 months ago

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

Savara Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

Savara Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Nov 5, 2025, 5:54 PM EST - 6 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRA

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

Oct 31, 2025, 4:05 PM EDT - 6 months ago

Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 30, 2025, 11:05 AM EDT - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Oct 29, 2025, 9:43 PM EDT - 6 months ago

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants

Savara Announces Proposed Public Offering

Oct 29, 2025, 4:07 PM EDT - 6 months ago

Savara Announces Proposed Public Offering

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Oct 29, 2025, 4:01 PM EDT - 6 months ago

Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 28, 2025, 9:58 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 23, 2025, 1:36 PM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Savara Announces Chief Medical Officer (CMO) Transition

Oct 17, 2025, 8:05 AM EDT - 7 months ago

Savara Announces Chief Medical Officer (CMO) Transition

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

Oct 14, 2025, 12:14 PM EDT - 7 months ago

SAVARA DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Reminds Savara Investors to Contact the Firm Before the November 7th Deadline

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

Oct 12, 2025, 8:44 AM EDT - 7 months ago

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Oct 6, 2025, 8:45 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Oct 2, 2025, 4:05 PM EDT - 7 months ago

Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Sep 29, 2025, 2:00 AM EDT - 7 months ago

Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025

Savara Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 1:00 PM EDT - 8 months ago

Savara Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Savara Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 4:30 PM EDT - 8 months ago

Savara Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

Sep 2, 2025, 9:00 AM EDT - 8 months ago

Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Aug 20, 2025, 5:15 PM EDT - 9 months ago

New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Aug 18, 2025, 8:05 AM EDT - 9 months ago

Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025

Richterscale
Richterscale Apr. 30 at 7:28 PM
$SVRA news?
2 · Reply
PennOhio
PennOhio Apr. 29 at 3:29 PM
$SVRA I don’t take way that at all. The FDA asked for more data and that triggered further review per guidance/proceed.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 29 at 2:42 AM
$SVRA RSI: 31.30, MACD: -0.1010 Vol: 0.34, MA20: 5.55, MA50: 5.48 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Stormvyre
Stormvyre Apr. 25 at 6:26 AM
$SVRA 👀
0 · Reply
Danboo
Danboo Apr. 24 at 9:13 PM
$SVRA Surfactant dysfunction is a hallmark disease element of aPaP which the Savara investigational drug is designed to address. Similarly, surfactant dysfunction is a hallmark element of COPD. FDA approval of the Savara drug opens the door to investigational expansion or off-label therapeutic expansion into the COPD disease population. Medinfo
0 · Reply
Danboo
Danboo Apr. 24 at 8:47 PM
$SVRA When Savara first went public there was a massive dilution of then Savara stock into new shares. The current proxy statement now calls for approval of expanding share authorization from 300 M to 600M. This suggests that upon FDA approval Savara management may authorize a stock split to restore partially or entirely pre dilution shares to investors. Medinfo
2 · Reply
Richterscale
Richterscale Apr. 24 at 5:10 PM
$SVRA When s the buyout ?
0 · Reply
ckruel
ckruel Apr. 24 at 1:51 PM
$SVRA Oppenheimer analyst Mazahir Alimohamed assumed coverage of Savara (SVRA) with an Outperform rating with a price target of $11, up from $9. With Priority Review granted to the BLA for molgramostim, an inhaled GM-CSF therapy, Savara’s story has shifted toward regulatory execution and commercial positioning, the firm says. Robust data from Phase 3 IMPALA-2 in autoimmune PAP support the BLA package and the firm’s view of a high-probability approval story, also given that prior FDA feedback was only CMC-related.
0 · Reply
notreload_ai
notreload_ai Apr. 24 at 12:12 PM
Oppenheimer initiates coverage on $SVRA with an Outperform rating and a $11 price target, following the FDA Priority Review designation for molgramostim. https://notreload.xyz/xy/oppenheimer-turns-bullish-on-savara-as-molgramostim-moves-closer-to-approval/
0 · Reply
Richterscale
Richterscale Apr. 23 at 8:58 PM
$SVRA Re started position $4.94.
0 · Reply
Richterscale
Richterscale Apr. 22 at 6:21 PM
$SVRA IMO this slides until it gets a little closer to the May presentation in FL
1 · Reply
art62
art62 Apr. 21 at 7:55 PM
$SVRA Does an AI CEO require millions of diluting shares?
1 · Reply
Richterscale
Richterscale Apr. 21 at 6:39 PM
$SVRA heading back to $5 for a while
1 · Reply
Spacemonkey1
Spacemonkey1 Apr. 21 at 4:51 PM
$SVRA same pattern here as everywhere, economy got bad news this morning with record low consumer confidence, seen plummeting prices coinciding with this news
0 · Reply
Spacemonkey1
Spacemonkey1 Apr. 21 at 4:37 PM
$SVRA we’ll see if this falls back into accumulation range
0 · Reply
Spacemonkey1
Spacemonkey1 Apr. 17 at 1:26 PM
$SVRA one positive will be that Vinay Prasad, and his war on drugs for rare diseases, will be gone from the FDA. Can’t leave soon enough.
0 · Reply
Richterscale
Richterscale Apr. 16 at 7:22 PM
$SVRA I’m out sold everything. Taking profits and a break till I can process the information
1 · Reply
Spacemonkey1
Spacemonkey1 Apr. 16 at 4:48 PM
$SVRA Not citing any safety, manufacturing, or efficacy concerns is a load of bullshit. Why else did they delay unless they got new info that raises more questions? Bullshit spin job by Savara, continuing their dismissal of investors
0 · Reply
Spacemonkey1
Spacemonkey1 Apr. 16 at 4:40 PM
$SVRA for defenders of Matthew Paul’s, this is yet another fiasco. Time to stop rewarding failure.
0 · Reply
PennOhio
PennOhio Apr. 16 at 11:09 AM
$SVRA the quote is: “The Agency did not cite any safety, efficacy, or manufacturing concerns in their correspondence.” Also, the PR clearly cited the reason “The FDA determined that the Company’s responses to recent information requests by the Agency constituted a major amendment to the BLA, resulting in a three-month extension of the PDUFA date.” Let’s hope this additional info (which can typically extend the review time) is beneficial to approval and label.
1 · Reply
Flydown
Flydown Apr. 16 at 8:26 AM
$SVRA If the FDA extended the approval period by three months without raising concerns about efficacy, safety, and chemical/manufacturing for the second time, then the drug's approval rate is extremely high. So why isn't the stock taking off like other biotechs?
1 · Reply
art62
art62 Apr. 15 at 10:37 PM
$SVRA So..."is unrelated to safety/efficacy/CMC concerns (but rather FDA bandwidth). " is key takeaway
0 · Reply